If we dare to ignore the usual 'garden gate' taunters, it is indeed great news for patients. What the release didn't mention is 20 year survival in kidney transplant patients is something like 46% (deceased donors) to 67% at 20 years (live donors).
It is indeed a development to be celebrated if CYP can help improve those rates, if we can get by the usual acrimony on here....
CYP Price at posting:
28.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)